Ampio Pharmaceuticals Company Profile (NASDAQ:AMPE)

Analyst Ratings

Consensus Ratings for Ampio Pharmaceuticals (NASDAQ:AMPE) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Ampio Pharmaceuticals (NASDAQ:AMPE)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016Janney Montgomery ScottReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Ampio Pharmaceuticals (NASDAQ:AMPE)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Ampio Pharmaceuticals (NASDAQ:AMPE)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ampio Pharmaceuticals (NASDAQ:AMPE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ampio Pharmaceuticals (NASDAQ:AMPE)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Ampio Pharmaceuticals (NASDAQ:AMPE)
DateHeadline
05/10/16 07:48 AMAmpio Launches Clinical Trial of AMPION™ for the Treatment of Osteoarthritis of the Hand May 10, 2016 - [at noodls] - ENGLEWOOD, Colo., May 10, 2016 /PRNewswire/ - Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that patient dosing has begun in the initial clinical trial of Ampion for the treatment of pain ...
05/10/16 07:33 AM8:33 am Ampio Pharma initiates clinical trial of Ampion for the treatment of pain due to osteoarthritis of the hand -
05/10/16 07:30 AMAmpio Launches Clinical Trial of AMPION™ for the Treatment of Osteoarthritis of the Hand - [PR Newswire] - ENGLEWOOD, Colo., May 10, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that patient dosing has begun in the initial clinical trial of Ampion™ for the treatment of pain due to osteoarthritis of the hand. Michael Macaluso, Ampio's CEO, noted: "The World Health Organization (1) has determined that Osteoarthritis (OA) will be the fourth leading cause of disability world wide by the year 2020.
05/06/16 08:07 AMAMPIO PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report -
05/03/16 07:40 AMAmpio Reports Additional Peer-Reviewed Publications on Ampion™ May 3, 2016 - [at noodls] - ENGLEWOOD, Colo., May 3, 2016 /PRNewswire/ - Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today the acceptance of three new publications in peer-reviewed scientific forums that report mechanisms ...
05/03/16 07:30 AMAmpio Reports Additional Peer-Reviewed Publications on Ampion™ - [PR Newswire] - ENGLEWOOD, Colo., May 3, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today the acceptance of three new publications in peer-reviewed scientific forums that report mechanisms ...
03/29/16 02:39 PMAmpio Pharmaceuticals : Completes Enrollment in Pivotal Clinical Trial of N(TM) - ENGLEWOOD, Colo., March 29, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that enrollment is now complete in the PIVOT trial of Ampion(TM) for the treatment of pain due to osteoarthritis-of-the-knee (OAK). http ...
03/18/16 05:25 AMPlaystation's version of virtual reality to debut in October - If we go with the lower price, the PSVR would cost customers $444.07. Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE) traded 173530 shares and its share price increased 9.48% to close at $2.31. Yamana Gold Inc. was the topic in 22 analyst reports since July 22 ...
03/07/16 03:45 PMAMPIO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pr -
03/05/16 12:04 PMAMPIO PHARMACEUTICALS, INC. Financials -
02/26/16 08:25 AMAMPIO PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report -
02/11/16 06:30 AMAmpio Clarifies ATM Program - [PR Newswire] - ENGLEWOOD, Colo., Feb. 11, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today, that on February 10, 2016, it entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. ("Cantor Fitzgerald"). Michael Macaluso, Chairman and CEO, stated "During our most recent conference call, we stated that we are not currently raising money and that we have enough money to get us through 2016 and into 2017 and still complete all of our current objectives and nothing has changed since that conference call.
02/10/16 03:46 PMAMPIO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S -
01/29/16 08:02 AMAMPIO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure -
01/26/16 07:30 AMAmpio's OptimEyes Study Results to be presented at The Association for Research in Vision and Ophthalmology (ARVO) - [PR Newswire] - ENGLEWOOD, Colo., Jan. 26, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the Abstract titled: "Potential Beneficial Effect of Low Dose Danazol in Combination with Renin Angiotensin System Inhibitors in Diabetic Macular Edema: a 12-week Multicenter Double-Blind Randomized Controlled Trial " was accepted by The Association for Research in Vision and Ophthalmology Conference (ARVO 2016) for presentation. This acceptance and presentation are in addition to the previously announced acceptance and presentation at the World Ophthalmology Congress to be held in Guadalajara, Mexico.
01/25/16 07:37 AMAmpio Announces 2016 Corporate Update on Thursday, January 28, 4:30pm EST January 25, 2016 - [at noodls] - ENGLEWOOD, Colo., January 25, 2016 /PRNewswire/ - Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced dial in details for a scheduled 2016 Corporate Update on Thursday, January 28, 4:30pm EST. ...
01/04/16 08:28 AMThe NYSE Establishes January 5, 2016 as the Ex-Distribution Date for the Ampio Distribution of Aytu BioScience Stock to Ampio Shareholders December 1, 2015 - [at noodls] - ENGLEWOOD, Colo., Dec. 1, 2015 /PRNewswire/ - Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the New York Stock Exchange has established January 5, 2016 as the ex-distribution date for ...
12/18/15 06:35 AMHow it All Plays Out - Free Research Reports on Hill International, Marinus Pharmaceuticals, Ampio Pharmaceuticals and Cutera - [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hill International ...
12/16/15 03:12 PMAMPIO PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -

Social

About Ampio Pharmaceuticals

No company description available

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AMPE
  • CUSIP:
Key Metrics:
  • Previous Close: $0.99
  • 50 Day Moving Average: $1.99
  • 200 Day Moving Average: $2.69
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $51.50M
  • Current Year EPS Consensus Estimate: $-0.61 EPS
  • Next Year EPS Consensus Estimate: $-0.19 EPS
Additional Links:
Ampio Pharmaceuticals (NASDAQ:AMPE) Chart for Saturday, July, 30, 2016